TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07831824: A Prospective Phase 2/3, Multicenter, Open Label Study of [68Ga]- LNTH2401 PET/CT Imaging in Participants With Prostate Cancer: Phase 2 Dose Optimization in Either Newly Diagnosed or Biochemically Recurrent Prostate Canc

Sponsor: Lantheus Medical Imaging · Phase: PHASE2/PHASE3 · Area: ONCOLOGY · Target Enrollment: 408 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$18,036,480

Rescue Site Savings

+$11,892,804

Unlock Full NCT07831824 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07831824 Rescue Dossier →